Independent market intelligence on healthcare AI, analytics, and Australian health policy — evidence-rated, free to read, and filtered for Australian relevance.
Connecting healthcare AI, Australian health policy, and pharmaceutical developments into strategic intelligence.
Clinical AI, diagnostic imaging, AI scribes, drug discovery, remote monitoring, and the regulatory frameworks shaping adoption across the sector.
Federal and state health policy, PBS/Medicare changes, retail pharmacy, digital health, workforce pressures, and system reform from an Australia-first perspective.
Drug approvals, clinical trial results, pricing and reimbursement, supply chain, biotech innovation, M&A activity, and commercial developments with Australian market relevance.
Each issue monitors the developments that matter — evidence-based, Australia-first, with a clear view on strategic, regulatory, and commercial implications.
How direct is LillyDirect? Not as direct as the headlines say. The US, UK and Australian versions compared, how an order and a pen each reach the patient, and what has not been made public.
The AIChemist sits at the intersection of advanced data science, artificial intelligence, healthcare, pharma, and policy — transforming raw signals into strategic intelligence.
Like the alchemist's pursuit of transmutation, The AIChemist combines technical depth in data science and AI with genuine healthcare domain knowledge — surfacing insights that are evidence-based, clearly assessed, and practically relevant.